PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

Novartis hits another setback in plan to repurpose rare disease drug in lung cancer

Novartis’ testing of canakinumab, which works by curbing inflammatory signaling in cells, for the seemingly unrelated use in lung cancer stems from an intriguing 2011 finding in a large study called CANTOS.

Set up to test whether reducing inflammation with canakinumab could curb heart disease, CANTOS suggested the drug lessened the incidence and lethality of a common type of lung cancer.

Novartis has spent the years since that study chasing the implications of its results. The Food and Drug Administration in 2018 rejected the company’s pitch to approve canakinumab as a treatment for reducing heart risk. And now the second trial designed to test canakinumab as a lung cancer treatment has come up short as well.

Novartis disclosed few details, except acknowledging that canakinumab did not significantly keep tumors from spreading or extend lives when added to Keytruda and platinum-based chemotherapy in previously untreated patients. Details from the Phase 3 study, called CANOPY-2, will be shared at an upcoming meeting, the company said.

The negative results follow data from another study, CANOPY-1, that showed no benefit to canakinumab when used later, as a treatment for lung cancer patients whose disease had progressed after chemotherapy and immunotherapy.

Neither trial tested canakinumab in a similar setting as CANTOS, however, which enrolled more than 10,000 people with heart disease who previously had a heart attack.

CANOPY-A, a study of canakinumab after surgery, more closely resembles the CANTOS study population, Novartis said. Results are expected in 2023 and could open a path for the drug in adjuvant use, if positive.

Novartis is also studying canakinumab in a Phase 2 trial testing the drug before surgery.

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40